Clinical implications of the intrinsic molecular subtypes of breast cancer
about
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingMolecular subtypes and imaging phenotypes of breast cancer.Breast cancer molecular subtypes: from TNBC to QNBCBI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtypeResistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancerOverview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPESFunctional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer.Oestrogen receptor negativity in breast cancer: a cause or consequence?Luminal B breast cancer: patterns of recurrence and clinical outcome.Epidemiology and survival outcome of breast cancer in a nationwide study.Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.High expression of COX5B is associated with poor prognosis in breast cancer.Bevacizumab Modulation of the Interaction Between the MCF-7 Cell Line and the Chick Embryo Chorioallantoic Membrane.Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Hereditary breast and ovarian cancer: new genes in confined pathways.Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer.Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity.Wnt signaling in triple-negative breast cancer.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cellsPapillotubular carcinoma with an invasive micropapillary carcinoma component of the breast, characterized by a rapid increase in size due to intra-tumoral hemorrhage: A case report.Ancestry as a potential modifier of gene expression in breast tumors from Colombian women.Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.A pathways-based prediction model for classifying breast cancer subtypes.Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients.Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.Genomic profiling of breast cancer in African-American women using MammaPrint.Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.
P2860
Q26747792-A4A50222-B9AD-46D7-8CBF-5BBCB784E9F9Q28069885-51D75B83-E777-42AD-87ED-23776CF30C82Q28076805-4E533018-118E-44B8-8CD3-EC2A9BE6C0E0Q30358627-F63494A1-61C8-49F1-9888-0BE18CFA9E73Q33659361-23FA8ADE-D104-40C9-A3B0-A95BADE8B39BQ33706962-C7978786-F280-4A69-9ADC-E4ED3EE958C7Q36110285-4B4A80D4-F82E-4121-99CC-9ECBDEC05955Q36111215-901B293D-6355-48D9-B9D0-F4EAEAB7C143Q36383626-3BB1957E-BCC5-4C77-9844-70F9526A8443Q36547919-86AE9327-3EF0-4AE0-9D67-DCBF63B94AA5Q36784065-23A8897F-3916-422A-8C7E-3ABE2A325869Q36867680-29972DC3-CAD7-43A1-8D82-E372CBE29DF7Q37457902-A420C3FC-99F2-477C-97CC-869C3CEC91C6Q37529397-AB1ABB22-ECCB-4D45-BDC9-0C9641ED4D78Q37662184-FB638805-8488-4B5E-A5EB-31CE0C793448Q37725545-822C1864-060E-4B2E-B5BA-E0AD820C6EB5Q38641240-D87761CB-AB7C-48CD-B32F-C9FC2E3514F1Q38673586-2CE15384-2629-4080-8D57-A7923E9F4D80Q38709589-733A0306-9E0D-4E21-B2AB-7480EB3B438CQ38747875-D0126CD3-0218-40DE-9806-A79A077BBF0EQ38786102-DC26575A-026A-4ED7-94BB-B2407D279EF2Q38925408-8B30245D-369F-49AC-9429-81CA25F290DBQ38952768-1118A341-A0BA-418C-B96C-8D70AA26A558Q39021766-7A9A11AE-7D79-4231-8DBD-8022C6F4A3AEQ39122509-F20B083D-F6C3-44AA-9C74-0059485833C4Q39144794-C1FD21A5-8E12-442D-A1DB-9C1115D1186CQ39214992-7312744D-5784-4407-A6C7-C092D5E2A4DBQ39262474-CF248840-E8DF-4A7F-A5A7-AAE98F22CEB5Q39625095-FF1391A4-D900-4C8E-910C-83CF70AC2DECQ40053251-28EBF401-2399-4A93-942D-E455FFA886DBQ41050362-E14AA064-0281-435A-A6E5-04FCCB56BBD4Q41235051-42D8F7DB-F034-4D4E-9208-77BF00A24982Q41498719-AB687A2C-2944-49FD-B488-1D25FB82CCB7Q41659344-BD6A99CF-073F-4FEC-9FEC-04199852946FQ41709107-90C9DDE5-B76B-4D7C-8BA1-9F55DD93F56CQ42282489-83A2C4B3-9794-4BC4-BD05-4D394F4CC309Q42497114-5CD65408-F18C-4689-8C97-7FAAC73DC285Q42498238-0B388C0E-18A8-4763-8C1B-5392CD718AE2Q45134639-C6E9AED7-5D8B-4FC4-A3A5-01438430FB9EQ45933729-39113625-EEFF-4397-B95E-5816C6D7BC28
P2860
Clinical implications of the intrinsic molecular subtypes of breast cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinical implications of the intrinsic molecular subtypes of breast cancer
@ast
Clinical implications of the intrinsic molecular subtypes of breast cancer
@en
Clinical implications of the intrinsic molecular subtypes of breast cancer
@nl
type
label
Clinical implications of the intrinsic molecular subtypes of breast cancer
@ast
Clinical implications of the intrinsic molecular subtypes of breast cancer
@en
Clinical implications of the intrinsic molecular subtypes of breast cancer
@nl
prefLabel
Clinical implications of the intrinsic molecular subtypes of breast cancer
@ast
Clinical implications of the intrinsic molecular subtypes of breast cancer
@en
Clinical implications of the intrinsic molecular subtypes of breast cancer
@nl
P2093
P3181
P1433
P1476
Clinical implications of the intrinsic molecular subtypes of breast cancer
@en
P2093
Aleix Prat
Barbara Adamo
Estela Pineda
Lydia Gaba
Margarita Viladot
Montserrat Muñoz
Patricia Galván
P304
P3181
P356
10.1016/J.BREAST.2015.07.008
P407
P478
24 Suppl 2
P577
2015-08-05T00:00:00Z